|
|
Resources Equal Parity On March 23, 2010, President Obama signed the Affordable Care Act (ACA) into law. This puts in place comprehensive health insurance reforms that will roll out over four years and beyond. Health reform includes several key steps in the next 4 years. Medicaid will be expanded to allow more people at the lowest…
Education Series Number 5.2 February 2001 (Revised) Joycelyn Woods has a graduate degree in neuroscience and psychopharmacology. She has published in neuroscience journals and is recognized internationally for her methadone advocacy work. She is a recipient of the “Richard Lane Methadone Advocacy Award.” Basic Opioid Pharmacology All natural and synthetic opioids exhibit a three dimensional…
February 10, 2004 We were hoping that this wouldn’t happen in because some legislators had come out in the media with reservations about this bill. Not so! House Bill #4387 which adds new restrictions on MMT clinics into the WV Health Code was introduced Tuesday February 10. 2004. You can view the bill in it’s…
NAMA Board of Directors Zachary Talbott, MSW, CMA President [email protected] Sharon Larson, RN, MS, CMA Vice Pressident [email protected] Brenda Davis, MSW, CASAC-T, CMA Treasurer [email protected] Megan Marx-Varela, MPA Secretary [email protected] Joycelyn Sue Woods, MA, CARC, CMA Executive Director [email protected] Paul Bowman, CMA, CARC [email protected] Sara E. Gefvert, CRS/CPS, CMA Technology and Communications [email protected] Walter Ginter, CMA Recovery and Peer Services [email protected] Charles Hilger, MSW, LDAC [email protected] Claude Hopkins,…
Policy Statement Number 1 April 1994 The National Alliance of Methadone Advocates supports the concept of Medical Maintenance and the prescribing of methadone outside of the methadone clinic setting. Medical Maintenance was initially implemented for patients who had achieved a high level of functionally in society and were hindered by the regulations that were conceived…
Dr Andrew Byrne, Medical Practitioner, Drug and Alcohol New South Wales, Australia Email – [email protected] September 23, 2003 This study randomised consenting heroin dependent subjects to receive one month’s treatment with (i) buprenorphine, (ii) buprenorphine/naloxone or (iii) placebo. For a further 11 months, surviving (sic) patients were followed in an open-label manner for primary outcome…